var data={"title":"Ondansetron: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ondansetron: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6684?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ondansetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ondansetron: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ondansetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ondansetron: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203706\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zofran;</li>\n      <li>Zofran ODT;</li>\n      <li>Zuplenz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203707\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Ondansetron;</li>\n      <li>AG-Ondansetron;</li>\n      <li>Apo-Ondansetron;</li>\n      <li>Bio-Ondansetron;</li>\n      <li>Dom-Ondansetron;</li>\n      <li>IPG-Ondansetron;</li>\n      <li>JAMP-Ondansetron;</li>\n      <li>Mar-Ondansetron;</li>\n      <li>Mint-Ondansetron;</li>\n      <li>Mylan-Ondansetron;</li>\n      <li>NAT-Ondansetron;</li>\n      <li>Nu-Ondansetron;</li>\n      <li>Ondansetron Hydrochloride Dihydrate Injection;</li>\n      <li>Ondansetron Injection;</li>\n      <li>Ondansetron Injection USP;</li>\n      <li>Ondansetron-Omega;</li>\n      <li>Ondissolve ODF;</li>\n      <li>PHL-Ondansetron;</li>\n      <li>PMS-Ondansetron;</li>\n      <li>Priva-Ondansetron;</li>\n      <li>RAN-Ondansetron;</li>\n      <li>ratio-Ondansetron;</li>\n      <li>Sandoz-Ondansetron;</li>\n      <li>Sandoz-Ondansetron ODT;</li>\n      <li>Septa-Ondansetron;</li>\n      <li>Teva-Ondansetron;</li>\n      <li>Vanc-Ondansetron;</li>\n      <li>Zofran ODT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203757\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Selective 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203710\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Single IV doses &gt;16 mg are no longer recommended due to the potential for QT prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with emetogenic chemotherapy:</b> IV: 0.15 mg/kg/dose (maximum: 16 mg/dose) administered over 15 minutes for 3 doses, beginning 30 minutes prior to chemotherapy, followed by subsequent doses 4 and 8 hours after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with highly emetogenic chemotherapy:</b> Oral: 24 mg 30 minutes prior to the start of single-day chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy:</b> Oral: 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1 to 2 days after chemotherapy completed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations: </i></b> <b>Prevention of chemotherapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Clinical Oncology (ASCO [Hesketh 2017]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High emetic risk, including most anthracyclines combined with cyclophosphamide regimens: Day(s) chemotherapy is administered (antiemetic regimen also includes dexamethasone, an NK<sub>1</sub> receptor antagonist, and olanzapine):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 8 mg or 0.15 mg/kg (maximum: 16 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 8 mg twice daily <b>or</b> three 8 mg oral soluble films (total dose 24 mg) once</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate emetic risk: Day(s) chemotherapy is administered (antiemetic regimen also includes dexamethasone [and an NK<sub>1</sub> receptor antagonist for carboplatin AUC &ge;4]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 8 mg or 0.15 mg/kg (maximum: 16 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 8 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetic risk:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 8 mg or 0.15 mg/kg (maximum: 16 mg/dose) prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 8 mg prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) (Roila 2016): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Highly emetic chemotherapy, (antiemetic regimen includes dexamethasone and aprepitant/fosaprepitant):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 8 mg or 0.15 mg/kg (maximum: 16 mg/dose) as a single dose prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 16 mg as a single dose prior to chemotherapy (8 mg twice daily has also been used)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderately emetic chemotherapy (antiemetic regimen includes dexamethasone [and aprepitant/fosaprepitant for AC chemotherapy regimen]):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IV: 8 mg or 0.15 mg/kg (maximum: 16 mg/dose) as a single dose prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oral: 16 mg (as 8 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetic risk: Ondansetron (dose not specified) prior to chemotherapy on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of radiation therapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Total body irradiation:</i> Oral: 8 mg administered 1 to 2 hours before each daily fraction of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single high-dose fraction radiotherapy to abdomen:</i> Oral: 8 mg administered 1 to 2 hours before irradiation, then 8 mg every 8 hours after first dose for 1 to 2 days after completion of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Daily fractionated radiotherapy to abdomen:</i> Oral: 8 mg administered 1 to 2 hours before irradiation, then 8 mg every 8 hours after first dose for each day of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>American Society of Clinical Oncology Antiemetic Guideline recommendations (ASCO [Hesketh 2017]):</b></i> Give before each fraction throughout radiation therapy for high emetic risk (with dexamethasone; continue for at least 24 hours after completion) and for moderate emetic risk (with or without dexamethasone before the first 5 fractions). For low emetic risk, may give either as prevention or rescue; for minimal emetic risk, give as rescue (if rescue used for either low or minimal emetic risk, then prophylaxis should be given until the end of radiation therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (off-label route/dosing): 8 mg or 0.15 mg/kg (maximum: 16 mg/dose) once or twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 8 mg once or twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative nausea and vomiting (PONV):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 4 mg as a single dose (over 2 to 5 minutes if giving IV) administered ~30 minutes before the end of anesthesia (see <b>Note</b> below).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The manufacturer recommends administration immediately before induction of anesthesia; however, this has been shown not to be as effective as administration at the end of surgery (Sun, 1997). Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 16 mg administered 1 hour prior to induction of anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of postoperative nausea and vomiting (off-label):</b> IV: 4 mg as a single dose for failure when an agent from a different class was utilized as prophylaxis <b>or</b> 1 mg may be effective when a prophylactic agent was not utilized (Gan 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nausea and vomiting of pregnancy (severe or refractory) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 8 mg administered over 15 minutes every 12 hours (Arsenault 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 8 mg every 12 hours (Arsenault 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203733\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ondansetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ondansetron: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with emetogenic chemotherapy</b>: Infants &ge;6 months, Children, and Adolescents: IV: 0.15 mg/kg/dose (maximum: 16 mg/dose) over 15 minutes for 3 doses, beginning 30 minutes prior to chemotherapy, followed by subsequent doses administered 4 and 8 hours after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: 4 mg 30 minutes before chemotherapy; repeat 4 and 8 hours after initial dose, then 4 mg 3 times a day for 1 to 2 days after chemotherapy completed</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Children &ge;12 years:</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Tablet: 8 mg 30 minutes before chemotherapy; repeat 8 hours after initial dose, then 8 mg twice daily (every 12 hours) for 1 to 2 days after chemotherapy completed.</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Soluble film: 8 mg orally twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose, then 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Guideline recommendations: Prevention of chemotherapy-induced nausea and vomiting: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Pediatric Oncology Group of Ontario (POGO)</i>\n        <i>(off-label dosing; Dupuis 2013; Patel 2017</i></b>\n      <b>\n        <i>):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Highly emetogenic chemotherapy: Infants &ge;1 month and Children &lt;12 years: IV, Oral: 0.15 mg/kg/dose (5 mg/m<sup>2</sup>/dose) prior to chemotherapy and then every 8 hours; maximum recommended IV dose: 16 mg. Antiemetic regimen also includes dexamethasone</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Highly emetogenic chemotherapy: Children &ge;12 years and Adolescents: IV, Oral: 0.15 mg/kg/dose (5 mg/m<sup>2</sup>/dose) prior to chemotherapy and then every 8 hours; maximum recommended IV dose: 16 mg. Antiemetic regimen includes dexamethasone and if no known or suspected drug interactions, aprepitant.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderately emetogenic chemotherapy: Infants &ge;1 month, Children, and Adolescents: IV, Oral: 0.15 mg/kg/dose (5 mg/m<sup>2</sup>/dose; maximum: 8 mg dose); prior to chemotherapy and then every 12 hours. Antiemetic regimen also includes dexamethasone.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetogenicity chemotherapy: Infants &ge;1 month, Children, and Adolescents: IV, Oral: 0.3 mg/kg/dose (10 mg/m<sup>2</sup>/dose; maximum IV dose: 16 mg) prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Prevention of postoperative nausea and vomiting (PONV):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;1 month and Children &le;12 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;40 kg: 0.1 mg/kg as a single dose over 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: 4 mg as a single dose over 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;12 years: IV, IM: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203711\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Oral, IV: No dosing adjustment required; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203712\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: No dosage adjustment is necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: No dosage adjustment necessary; however, according to the manufacturer, there is no experience for oral ondansetron in renal impairment beyond first-day administration (has not been studied beyond day 1).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203713\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Mild to moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">Severe impairment (Child-Pugh class C):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Day 1: Maximum daily dose: 8 mg; however, according to the manufacturer, (there is no experience beyond first-day administration (has not been studied beyond day 1)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Maximum daily dose: 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203680\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Film, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zuplenz: 4 mg (1 ea [DSC], 10 ea [DSC], 30 ea); 8 mg (1 ea [DSC], 10 ea [DSC], 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 40 mg/20 mL (20 mL [DSC]) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/2 mL (2 mL); 40 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12 mg/50 mL in NaCl 0.9% (50 mL); 16 mg/50 mL in NaCl 0.9% (50 mL); 8 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 4 mg/5 mL (50 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/5 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 24 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran ODT: 4 mg, 8 mg [contains aspartame, methylparaben sodium, propylparaben sodium; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203666\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25320531\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203683\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Oral dosage forms should be administered 30 minutes prior to chemotherapy; 1 to 2 hours before radiotherapy; 1 hour prior to the induction of anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally disintegrating tablets: Do not remove from blister until needed. Peel backing off the blister, do not attempt to push tablet through the foil. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva (no need to administer with liquids).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral soluble film: Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4 to 20 seconds). Swallow with or without liquid. If using more than one film, each film should be allowed to dissolve completely before administering the next film.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Should be administered undiluted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IVPB: Infuse diluted solution over 15 minutes; 24-hour continuous infusions have been reported, but are rarely used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Prevention of postoperative nausea and vomiting: Single doses may be administered IV injection as undiluted solution over at least 30 seconds but preferably over 2 to 5 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203682\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer chemotherapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (including high-dose cisplatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy (including cisplatin &ge;50 mg/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiotherapy-associated nausea and vomiting:</b> Oral: Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and/or vomiting:</b> IV and Oral: Prevention of postoperative nausea and/or vomiting (PONV). If nausea/vomiting occur in a patient who had not received prophylactic ondansetron, IV ondansetron may be administered to prevent further episodes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Routine prophylaxis for PONV in patients with minimal expectation of nausea and/or vomiting is not recommended, although use is recommended in patients when nausea and vomiting must be avoided in the postoperative period, even if the incidence of PONV is low.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469498\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Nausea and vomiting of pregnancy (severe or refractory); Postoperative nausea and vomiting (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203765\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ondansetron may be confused with dolasetron, granisetron, palonosetron </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran may be confused with Zantac, Zosyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203673\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Percentages reported in adult patients unless otherwise specified. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (oral: 9% to 27%; IV: 17%), fatigue (oral: &le;9% to 13%), malaise (oral: &le;9% to 13%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (6% to 11%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness (IV: &le;8%), sedation (IV: &le;8%), (dizziness (7%), agitation (oral: &le;6%), anxiety (oral: &le;6%), paresthesia (IV: 2%), sensation of cold (IV: 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (2% to 5%), skin rash (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (oral: 6% to 7%; IV: Children 1 to 24 months of age: 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Gynecologic disease (oral: 7%), urinary retention (oral: 5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (&gt;2 times ULN: 1% to 5%; transient), increased serum AST (&gt;2 times ULN: 1% to 5%; transient) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (IV: 4%; includes burning sensation at injection site, erythema at injection site, injection site pain) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Hypoxia (oral: 9%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (2% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, accommodation disturbance, anaphylactoid reaction, anaphylaxis, angina pectoris, angioedema, atrial fibrillation, bradycardia, bronchospasm, bullous skin disease, cardiac arrhythmia, cardiorespiratory arrest (IV), chest pain, chills, depression of ST segment on ECG, dyspnea, dystonic reaction, ECG changes, extrapyramidal reaction (IV), flushing, hepatic failure (when used with other hepatotoxic medications), hiccups, hypersensitivity reaction, hypokalemia, hypotension, ischemic heart disease, laryngeal edema, laryngospasm (IV), liver enzyme disorder, mucosal tissue reaction, myocardial infarction, neuroleptic malignant syndrome, oculogyric crisis, palpitations, positive lymphocyte transformation test, prolonged Q-T interval on ECG (dose dependent), second-degree atrioventricular block, serotonin syndrome, shock (IV), Stevens-Johnson syndrome, stridor, supraventricular tachycardia, syncope, tachycardia, tonic-clonic seizures, torsades de pointes, toxic epidermal necrolysis, transient blindness (lasted &le;48 hours), transient blurred vision (following infusion), urticaria, vascular occlusive events, ventricular premature contractions, ventricular tachycardia, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203687\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203670\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis and bronchospasm) have been reported; discontinue if hypersensitivity occurs. Use with caution in patients allergic to other 5-HT3 receptor antagonists; cross-reactivity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: ECG changes, including dose-dependent QT interval prolongation, have been observed with ondansetron use. Cases of torsade de pointes have also been reported. Selective 5-HT<sub>3</sub> antagonists, including ondansetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT), usually occurring 1 to 2 hours after IV administration. Single doses &gt;16 mg ondansetron IV are no longer recommended due to the potential for an increased risk of QT prolongation. In most patients, these changes are not clinically relevant; however, when used in conjunction with other agents that prolong these intervals or in those at risk for QT prolongation, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics) or in patients with cardiovascular disease, clinically relevant QT interval prolongation may occur resulting in torsades de pointes. A number of trials have shown that 5-HT<sub>3</sub> antagonists produce QT interval prolongation to variable degrees. Avoid ondansetron use in patients with congenital long QT syndrome. Use caution and monitor ECG in patients with other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], heart failure, bradyarrhythmias, and cumulative high-dose anthracycline therapy). Reduction in heart rate may also occur with the 5-HT<sub>3</sub> antagonists. IV formulations of 5-HT<sub>3</sub> antagonists have more association with ECG interval changes, compared to oral formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonist have occurred in a postanesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of ondansetron. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Dose limitations are recommended for patients with severe hepatic impairment (Child-Pugh class C); use with caution in mild-moderate hepatic impairment; clearance is decreased and half-life increased in hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Orally-disintegrating tablets contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (Roila 2016). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease, concurrent morbidities and medications to assure antiemetic regimen is optimized (ASCO [Hesketh 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ileus or gastric distention: Ondansetron does not stimulate gastric or intestinal peristalsis (do not use in place of nasogastric suction). Ondansetron may mask progressive ileus and/or gastric distension; monitor for decreased bowel activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203750\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203675\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9719&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Ondansetron may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: Ondansetron may enhance the arrhythmogenic effect of Panobinostat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203703\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Tablet: Food slightly increases the extent of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203677\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203690\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu 2006). Due to pregnancy-induced physiologic changes, clearance of ondansetron may increase as pregnancy progresses (Lemon 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although ondansetron has been evaluated for the treatment of nausea and vomiting of pregnancy, current guidelines note data related to fetal safety is conflicting (ACOG 2015); ondansetron is generally reserved for use when other agents have failed (Arsenault 2002). Because a dose-dependent QT-interval prolongation occurs with use, the manufacturer recommends ECG monitoring in patients with electrolyte abnormalities (which can be associated with some cases of NVP; Koren 2012). An international consensus panel recommends that 5-HT<sub>3</sub> antagonists (including ondansetron) should not be withheld in pregnant patients receiving chemotherapy for the treatment of gynecologic cancers, when chemotherapy is given according to general recommendations for chemotherapy use during pregnancy (Amant 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16565637\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ondansetron is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203691\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F554062\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG (if applicable in high-risk or elderly patients); potassium, magnesium. Monitor for signs of serotonin syndrome; monitor for decreased bowel activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203669\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ondansetron is a selective 5-HT<sub>3</sub>-receptor antagonist which blocks serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203686\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 100%; nonlinear absorption occurs with increasing oral doses; Zofran ODT tablets are bioequivalent to Zofran tablets; absorption does not occur via oral mucosa </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: Surgical patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to 4 months: 3.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 to 24 months: 2.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3 to 12 years: 1.65 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: Cancer patients: 4 to 18 years: 1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 70% to 76%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, and CYP3A4 substrate; some demethylation occurs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 50% to 70% due to some first-pass metabolism; in cancer patients (adults) 85% to 87% bioavailability possibly related to changes in metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Children: Cancer patients: Children and Adolescents: 4 to 18 years: 2.8 hours; Surgical patients: Infants 1 to 4 months: 6.7 hours; Infants and Children 5 months to 12 years: 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Adults: 3 to 6 hours; Mild-to-moderate hepatic impairment (Child-Pugh classes A and B): 12 hours; Severe hepatic impairment (Child-Pugh class C): 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: ~2 hours; Oral soluble film: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (44% to 60% as metabolites, ~5% as unchanged drug); feces (~25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients: Children and Adolescents 4 to 18 years: 0.599 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Surgical patients: Infants and Children: 1 to 4 months: 0.401 L/kg/hour; 5 to 24 months: 0.581 L/kg/hour; 3 to 12 years: 0.439 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adult (normal): 19 to 40 years: 0.381 L/kg/hour; 61 to 74 years: 0.319 L/kg/hour; &gt;75 years: 0.262 L/kg/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Film</b> (Zuplenz Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $1,158.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,158.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/2 mL (2 mL): $0.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/20 mL (20 mL): $6.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (50 mL): $239.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/50 mL 0.9% (50 mL): $7.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/50 mL 0.9% (50 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg/50 mL 0.9% (50 mL): $8.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zofran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (50 mL): $283.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Ondansetron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $668.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,113.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Zofran ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $26.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (1): $43.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ondansetron HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $742.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,209.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg (1): $105.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zofran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $837.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,394.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203692\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apulset (BD);</li>\n      <li>Avessa (LU);</li>\n      <li>Cedantron (ID);</li>\n      <li>Cetron (AR);</li>\n      <li>Danac (MX);</li>\n      <li>Dantron (TH, ZA);</li>\n      <li>Emeset (IN, LK);</li>\n      <li>Emetron (HU);</li>\n      <li>Emiset (BD);</li>\n      <li>Emistop (PH);</li>\n      <li>Emizof (IE);</li>\n      <li>Emodan (PH);</li>\n      <li>Enset (PH);</li>\n      <li>Finaber (PY);</li>\n      <li>Frazon (ID);</li>\n      <li>Glotron (ID);</li>\n      <li>Invomit (ID);</li>\n      <li>Izofran (CL, UY);</li>\n      <li>Lartron (MX);</li>\n      <li>Modifical (CO, EC);</li>\n      <li>Narfoz (ID);</li>\n      <li>Nausedron (BR);</li>\n      <li>Ofran (LK);</li>\n      <li>Ondak (CO);</li>\n      <li>Ondant (KR);</li>\n      <li>Ondavell (ID, PH, SG, TH);</li>\n      <li>Ondawi (LK);</li>\n      <li>Ondaz (AU);</li>\n      <li>Ondem (UA);</li>\n      <li>Ondran (IE);</li>\n      <li>Onetic (ID);</li>\n      <li>Onsat (BD);</li>\n      <li>Onset-8 (PH);</li>\n      <li>Onsetron (KR);</li>\n      <li>Onsett (TZ);</li>\n      <li>Onsia (TH);</li>\n      <li>Onzet (PH);</li>\n      <li>Onzod (TW);</li>\n      <li>Osetron (AU, BD);</li>\n      <li>Periset (BD);</li>\n      <li>Setofilm (ES, GB);</li>\n      <li>Setronax (HK, MY, SG, VN);</li>\n      <li>Trondamet (HK);</li>\n      <li>Vomceran (ID);</li>\n      <li>Vometron (ID);</li>\n      <li>Vomiof (IN);</li>\n      <li>Vomiz (TW);</li>\n      <li>Yatrox (ES);</li>\n      <li>Yunorm (UA);</li>\n      <li>Zemitron (QA);</li>\n      <li>Zetron (TH);</li>\n      <li>Zilfujim (AU);</li>\n      <li>Zofetron (UA);</li>\n      <li>Zofran (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UA, UG, VE, VN, YE, ZM, ZW);</li>\n      <li>Zofran Melt (AE, BH, KW, QA, SA);</li>\n      <li>Zofran ODT (BB);</li>\n      <li>Zofran Zydis (CR, DO, GT, KR, NI, NZ, PA, SV);</li>\n      <li>Zofron (GR);</li>\n      <li>Zophren (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. <i>Int J Gynecol Cancer</i>. 2009;19(suppl 1):S1-S12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/19509538/pubmed\" target=\"_blank\" id=\"19509538\">19509538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderka M, Mitchell AA, Louik C, et al, &quot;Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12405123\"></a>Arsenault MY, Lane CA, MacKinnon CJ, et al. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2002;24(10):817-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/12405123/pubmed\" target=\"_blank\" id=\"12405123\">12405123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einarson A, Maltepe C, Navioz Y, et al, &quot;The Safety of Ondansetron for Nausea and Vomiting of Pregnancy: A Prospective Comparative Study,&quot; <i>BJOG</i>, 2004, 111(9):940-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/15327608/pubmed\" target=\"_blank\" id=\"15327608\">15327608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferreira E, Gillet M, Leli&egrave;vre J, et al, &quot;Ondansetron Use During Pregnancy: A Case Series,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(1):e1-e10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/22267256/pubmed\" target=\"_blank\" id=\"22267256\">22267256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18042859\"></a>Gan TJ, Meyer TA, Apfel CC, et al, &quot;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&quot; <i>Anesth Analg</i>, 2007, 105(6):1615-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/18042859/pubmed\" target=\"_blank\" id=\"18042859\">18042859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28759346\"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, &quot;Motherisk Update. Is Ondansetron Safe for Use During Pregnancy?&quot; <i>Can Fam Physician</i>, 2012, 58(10):1092-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/23064917/pubmed\" target=\"_blank\" id=\"23064917\">23064917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo; <i>J Clin Oncol</i>, 2006, 24(18):2932-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/16717289/pubmed\" target=\"_blank\" id=\"16717289\">16717289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemon LS, Zhang H, Hebert MF, et al. Ondansetron exposure changes in a pregnant woman. <i>Pharmacotherapy</i>. 2016;36(9):e139-e141. doi: 10.1002/phar.1796.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/27374186/pubmed\" target=\"_blank\" id=\"27374186\">27374186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navari RM and Koeller JM, &ldquo;Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine<sub>3</sub> Receptor Antagonists,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(9):1276-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/12921512/pubmed\" target=\"_blank\" id=\"12921512\">12921512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B, Svanstr&ouml;m H, and Hviid A, &quot;Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes,&quot; <i>N Engl J Med</i>, 2013, 368(9):814-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/23445092/pubmed\" target=\"_blank\" id=\"23445092\">23445092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28453189\"></a>Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. <i>Pediatr Blood Cancer</i>. 2017;64(10).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/28453189/pubmed\" target=\"_blank\" id=\"28453189\">28453189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siu SS, Chan MT, and Lau TK, &quot;Placental Transfer of Ondansetron During Early Human Pregnancy,&quot; <i>Clin Pharmacokinet</i>, 2006, 45(4):419-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/16584287/pubmed\" target=\"_blank\" id=\"16584287\">16584287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sun R, Klein KW, and White PF, &quot;The Effect of Timing of Ondansetron Administration in Outpatients Undergoing Otolaryngologic Surgery,&quot; <i>Anesth Analg</i>, 1997, 84(2):331-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/9024023/pubmed\" target=\"_blank\" id=\"9024023\">9024023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan PC and Omar SZ, &quot;Contemporary Approaches to Hyperemesis During Pregnancy,&quot; <i>Curr Opin Obstet Gynecol</i>, 2011, 23(2):87-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/21297474/pubmed\" target=\"_blank\" id=\"21297474\">21297474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tramer MR, Moore RA, Reynolds DJ, et al, &ldquo;A Quantitative Systematic Review of Ondansetron in Treatment of Established Postoperative Nausea and Vomiting,&rdquo; <i>BMJ</i>, 1997, 314(7087):1088-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-drug-information/abstract-text/9133892/pubmed\" target=\"_blank\" id=\"9133892\">9133892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zofran (ondansetron) [prescribing information]. East Hanover, NJ: Norvartis Pharmaceuticals; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zofran (ondansetron) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zofran injection (ondansetron) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuplenz (ondansetron) [prescribing information]. Raleigh, NC: Midatech Pharma US Inc.; January 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9719 Version 275.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203706\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203707\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F203757\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F203710\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F203733\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F203711\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F203712\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F203713\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203680\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F203666\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F25320531\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F203683\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F203682\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469498\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203765\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203673\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203687\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203670\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F203750\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203675\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F203703\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203677\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F203690\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16565637\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F203691\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F554062\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203669\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F203686\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203692\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9719|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ondansetron-patient-drug-information\" class=\"drug drug_patient\">Ondansetron: Patient drug information</a></li><li><a href=\"topic.htm?path=ondansetron-pediatric-drug-information\" class=\"drug drug_pediatric\">Ondansetron: Pediatric drug information</a></li></ul></div></div>","javascript":null}